{"preliminary_commentary":{"by_channel":{"x_thread":26,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04630730\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-10-31T07:07:12.883Z","note":"Automated from the 26 newest of 27 indexed sources (Jan 2024 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":26,"text":"- Whether findings merit validation in larger comparative studies\n- Whether the approach can support bladder preservation and reduce cystectomy need\n- Whether rBCG adds benefit to perioperative chemo-immunotherapy\n- How the regimen fits with EV-P, including possible combination strategies\n\nAlso discussed: toxicity, patient selection."},"drugs_tested":[["VPM1002BC","atezolizumab","cisplatin","gemcitabine"]],"indication":"muscle-invasive bladder cancer","name":"SAKK 06/19","nct_id":"NCT04630730","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=sakk-06-19-nct04630730. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"The Intravesical recombinant BCG (Bacillus Calmette-Guérin - VPM1002BC) is used as an immuno-stimulating agent. The patient will receive 3 weekly BCG instillations as induction treatment.\n\n4 cycles of atezolizumab, a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1 inhibitor) will be administered in combination with the standard neoadjuvant chemotherapy cisplatin/gemcitabine.\n\nAfter surgery atezolizumab will be administered in the adjuvant setting for 13 cycles.","label":"Recombinant intravesical BCG","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-06","type":"ESTIMATED"},"conditions":["Bladder Cancer"],"enrollment":{"count":46,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)","otherNames":["VPM1002BC"],"type":"DRUG"},{"name":"Atezolizumab","otherNames":["Tecentriq™"],"type":"DRUG"},{"name":"Cisplatin","otherNames":["Platinol®"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":["Gemzar ®"],"type":"DRUG"}],"last_update":"2026-10-23","lead_sponsor":"Swiss Cancer Institute","official_title":"Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-04-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Pathological complete remission (pCR)","timeFrame":"At the date of tumor assessment after surgery, estimated at approximately 20 to 24 weeks after treatment start"}],"references":[{"citation":"Petrausch U, Spahn M, Schneider M, Hayoz S, Rentsch CA, Rothschild S, Omlin A, Cathomas R. Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19). BMJ Open. 2023 Jun 7;13(6):e067634. doi: 10.1136/bmjopen-2022-067634.","pmid":"37286312","type":"DERIVED"}],"start_date":{"date":"2022-06-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC","url":"https://clinicaltrials.gov/study/NCT04630730"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/sakk-06-19-nct04630730"}